Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Receivables - Other (2020 - 2023)

Historic Receivables - Other for Relay Therapeutics (RLAY) over the last 4 years, with Q1 2023 value amounting to $4.9 million.

  • Relay Therapeutics' Receivables - Other rose 521.28% to $4.9 million in Q1 2023 from the same period last year, while for Mar 2023 it was $4.9 million, marking a year-over-year increase of 521.28%. This contributed to the annual value of $4.9 million for FY2022, which is 828.74% up from last year.
  • Per Relay Therapeutics' latest filing, its Receivables - Other stood at $4.9 million for Q1 2023, which was up 521.28% from $4.9 million recorded in Q4 2022.
  • In the past 5 years, Relay Therapeutics' Receivables - Other registered a high of $8.6 million during Q1 2021, and its lowest value of $4.2 million during Q2 2021.
  • Its 4-year average for Receivables - Other is $5.3 million, with a median of $4.8 million in 2022.
  • Over the last 5 years, Relay Therapeutics' Receivables - Other had its largest YoY gain of 1526.7% in 2022, and its largest YoY loss of 4538.69% in 2022.
  • Relay Therapeutics' Receivables - Other (Quarter) stood at $7.7 million in 2020, then tumbled by 40.72% to $4.5 million in 2021, then rose by 8.29% to $4.9 million in 2022, then grew by 0.65% to $4.9 million in 2023.
  • Its Receivables - Other stands at $4.9 million for Q1 2023, versus $4.9 million for Q4 2022 and $4.9 million for Q3 2022.